Abcellera Biologics Inc

ABCL

3.270USD

-0.080-2.39%

Close 03/27, 16:00（ET）Quotes delayed by 15 min

Abcellera Biologics Inc's Score

Industry at a Glance

Industry Ranking

74 / 391

Overall Ranking

184 / 4542

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Abcellera Biologics Inc Highlights

StrengthsRisks

AbCellera Biologics Inc. discovers and develops antibody medicines for indications across therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. Its platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the challenging antibody discovery problems. It is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two internal programs, ABCL635 and ABCL575, are in late-preclinical studies. ABCL635 is an antibody drug candidate for metabolic and endocrine conditions, and ABCL575 is an antibody drug candidate with broad potential in inflammatory conditions and autoimmune diseases and an initial indication in atopic dermatitis. ABCL575 binds OX40L to disrupt OX40/OX40L signaling, a regulator of inflammatory pathways in AD. In addition to ABCL635 and ABCL575, it is advancing a pipeline of more than 20 internal discovery programs.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 97.58% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 75.13M.

Fairly Valued

The company’s latest PE is -6.67, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 112.27M shares, decreasing 0.09% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 54.60K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.75.

Analyst Rating

Based on 8 analysts

Buy

Current Rating

9.167

Target Price

+173.63%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Abcellera Biologics Inc is 7.98, ranking 57 out of 391 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is average. Its latest quarterly revenue reached 44.85M, representing a year-over-year increase of 788.18%, while its net profit experienced a year-over-year increase of 73.85%.

Score

Industry at a Glance

Previous score

7.98

Change

0



Financials

5.93

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

10.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

6.41

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.57

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Abcellera Biologics Inc is 7.59, ranking 97 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -6.67, which is -401.35% below the recent high of 20.10 and -542.51% above the recent low of -42.86.

Score

Industry at a Glance

Previous score

7.59

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 74/391

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Abcellera Biologics Inc is 8.00, ranking 163 out of 391 in the Biotechnology & Medical Research industry. The average price target is 9.50, with a high of 16.00 and a low of 7.00.

Score

Industry at a Glance

Previous score

8.00

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Abcellera Biologics Inc is 6.06, ranking 280 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 3.66 and the support level at 3.06, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.23

Change

-0.17

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Abcellera Biologics Inc is 5.00, ranking 136 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 50.73%, representing a quarter-over-quarter decrease of 1.98%. The largest institutional shareholder is James Simons, holding a total of 2.39M shares, representing 0.79% of shares outstanding, with 18.72% decrease in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Thermopylae Holdings Ltd

55.92M

-0.40%

Baker Bros. Advisors LP

27.53M

--

Capital World Investors

13.36M

--

Two Sigma Investments, LP

9.99M

+22.09%

Lecault (Veronique)

9.61M

--

ArrowMark Colorado Holdings, LLC

4.11M

--

Driehaus Capital Management, LLC

1.73M

+245.44%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Abcellera Biologics Inc is 4.09, ranking 108 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 0.87. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.

Abcellera Biologics Inc

ABCL

6.85 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.42 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Madrigal Pharmaceuticals Inc

MDGL

8.27 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.27 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Day One Biopharmaceuticals Inc

DAWN

8.26 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

IQVIA Holdings Inc

IQV

8.21 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment